ERBB2 and breast cancer: Previous studies also illustrated that ERβ negatively regulated HER2/HER3 and positively regulated PTEN in breast cancer, which subsequently inhibited the AKT pathway and resulted in the enhancement of tamoxifen sensitivity [23].